Sfoglia per AUTORE
BIELLO F
Collezione AOU San Luigi di Orbassano
Items : 2
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1?50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry. in Journal for immunotherapy of cancer / J Immunother Cancer. 2025 Feb 4;13(2):e010674. doi: 10.1136/jitc-2024-010674.
2025
AOU San Luigi di Orbassano
AOU Novara
AOU San Luigi di Orbassano
AOU Novara
Wakelee H; Garassino M; Peters S; Takada K; Naqash AR; Torri V; Hejleh TA; Ferrara R; Aerts JGJV; Aboubakar Nana F; Dingemans AM; Biello F; Rogado J; Moliner L; Beninato T; Lo Russo G; Servetto A; Mezquita L; Gorría T; Minuti G; Bennati C; Tonini G; Cortinovis DL; Agustoni F; Majem M; Baena J; Macerelli M; Monnet I; O'Reilly D; et alii...
Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumab. in Clinical and experimental medicine / Clin Exp Med. 2024 Aug 6;24(1):182. doi: 10.1007/s10238-024-01427-8.
2024
AOU San Luigi di Orbassano
AOU Novara
AOU San Luigi di Orbassano
AOU Novara
Gil-Bazo I; Baraibar I; Biello F; Rivoltini L; Chiari R; Baglivo S; Metro G; Passiglia F; Barletta G; Ludovini V; Rijavec E; Alama A; Dellepiane C; Dal Bello MG; Zullo L; Tagliamento M; Longo L; Vanni I; Rossi G; Ostano P; Santamaria S; Guana F; Chiorino G; Marconi S; Genova C; Novello S; Grossi F; Coco S;